Solo Pace Control System SOLOEPG1LRecalls & reported problems
Solo Pace Inc. · Solo Pace Control External Pulse Generator · Class 2
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 5
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 5 adverse event reports that list this exact device (DI 00850056280037), received between Apr 2, 2026 and Apr 3, 2026 — classified as 5 malfunctions.
The most frequently reported specific device problem is “Over-Sensing” (4 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Reports received per month
Most reported problems
Device problems
- Over-Sensing4
- Under-Sensing3
- Loose or Intermittent Connection1
Patient problems
- No Clinical Signs, Symptoms or Conditions5
Recent adverse event reports
The 5 most recent of 5 reports, in the reporter's own words as published by the FDA.
MalfunctionApr 3, 2026Loose or Intermittent Connection
CUSTOMER REPORTS THE DEVICE IS HAVING ISSUES PACING. NO PATIENT COMPLICATIONS WERE REPORTED AS A RESULT OF THIS PROBLEM.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24778655 ↗MalfunctionApr 2, 2026Over-Sensing; Under-Sensing
THE EPG FUNCTIONED AS DESIGNED IN VOO MODE DURING RAPID PACING AND 2 HEART VALVES WERE SUCCESSFULLY DEPLOYED. THE CONTINUITY TEST LIGHT INDICATOR GAVE A FALSE INDICATION THAT LEAD WIRE CONTINUITY WAS NOT INTACT, WHEN IN FACT THE CONTINUITY WAS INTACT AND THE SYSTEM WAS ABLE TO DELIVER APPROPRIATE CURRENT TO THE HEART AND PACE. IN ADDITION, THE EPG SENSING FUNCTION IN VVI MODE DID NOT FUNCTION AS DESIGNED. THERE WERE TIMES WHERE THERE WAS VENTRICULAR UNDERSENSING, AND ALSO TIMES WHERE THERE WAS VENTRICULAR OVERSENSING LEADING TO IRREGULARITIES IN PACING OUTPUT TIMING. THESE WERE ALL PRESENT AT LOW PACING RATES, AND IN NO CASE CAUSED AN ARRHYTHMIA OR HEMODYNAMIC INSTABILITY. NO PATIENT COMPLICATIONS WERE REPORTED AS A RESULT OF THIS PROBLEM.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24766963 ↗MalfunctionApr 2, 2026Over-Sensing
THE EPG FUNCTIONED AS DESIGNED IN VOO MODE DURING RAPID PACING AND THE HEART VALVE WAS SUCCESSFULLY DEPLOYED. THE EPG WAS OVER-SENSING WHEN IN VVI MODE DURING CAPTURE CHECK. THE OVER-SENSING OCCURRED BOTH AT 3MA AND 25MA PACING OUTPUTS. THE OVER-SENSING DID NOT CAUSE ARRHYTHMIAS OR HEMODYNAMIC INSTABILITY. NO PATIENT COMPLICATIONS WERE REPORTED AS A RESULT OF THIS PROBLEM.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24766962 ↗MalfunctionApr 2, 2026Over-Sensing; Under-Sensing
THE EPG FUNCTIONED AS DESIGNED IN VOO MODE DURING RAPID PACING AND 2 HEART VALVES WERE SUCCESSFULLY DEPLOYED. THE CONTINUITY TEST LIGHT INDICATOR GAVE A FALSE INDICATION THAT LEAD WIRE CONTINUITY WAS NOT INTACT, WHEN IN FACT THE CONTINUITY WAS INTACT AND THE SYSTEM WAS ABLE TO DELIVER APPROPRIATE CURRENT TO THE HEART AND PACE. IN ADDITION, THE EPG SENSING FUNCTION IN VVI MODE DID NOT FUNCTION AS DESIGNED. THERE WERE TIMES WHERE THERE WAS VENTRICULAR UNDERSENSING, AND ALSO TIMES WHERE THERE WAS VENTRICULAR OVERSENSING LEADING TO IRREGULARITIES IN PACING OUTPUT TIMING. THESE WERE ALL PRESENT AT LOW PACING RATES, AND IN NO CASE CAUSED AN ARRHYTHMIA OR HEMODYNAMIC INSTABILITY. NO PATIENT COMPLICATIONS WERE REPORTED AS A RESULT OF THIS PROBLEM.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24766961 ↗MalfunctionApr 2, 2026Over-Sensing; Under-Sensing
THE EPG FUNCTIONED AS DESIGNED IN VOO MODE DURING RAPID PACING AND 2 HEART VALVES WERE SUCCESSFULLY DEPLOYED. THE CONTINUITY TEST LIGHT INDICATOR GAVE A FALSE INDICATION THAT LEAD WIRE CONTINUITY WAS NOT INTACT, WHEN IN FACT THE CONTINUITY WAS INTACT AND THE SYSTEM WAS ABLE TO DELIVER APPROPRIATE CURRENT TO THE HEART AND PACE. IN ADDITION, THE EPG SENSING FUNCTION IN VVI MODE DID NOT FUNCTION AS DESIGNED. THERE WERE TIMES WHERE THERE WAS VENTRICULAR UNDERSENSING, AND ALSO TIMES WHERE THERE WAS VENTRICULAR OVERSENSING LEADING TO IRREGULARITIES IN PACING OUTPUT TIMING. THESE WERE ALL PRESENT AT LOW PACING RATES, AND IN NO CASE CAUSED AN ARRHYTHMIA OR HEMODYNAMIC INSTABILITY. NO PATIENT COMPLICATIONS WERE REPORTED AS A RESULT OF THIS PROBLEM.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24766960 ↗
Other Pulse-Generator, Pacemaker, External devices
- NA 5392Medtronic, Inc. · PULSE-GENERATOR, PACEMAKER, EXTERNAL1 death1,934 reports
- NA 5392Medtronic, Inc. · PULSE-GENERATOR, PACEMAKER, EXTERNAL2 deaths930 reports
- NA 5392Medtronic, Inc. · PULSE-GENERATOR, PACEMAKER, EXTERNAL2 deaths654 reports
- NA 5392Medtronic, Inc. · PULSE-GENERATOR, PACEMAKER, EXTERNAL504 reports
- NA 53401Medtronic, Inc. · PULSE-GENERATOR, PACEMAKER, EXTERNAL133 reports
- SoloPace EPG SOLOEPG1Solo Pace Inc. · Pulse-Generator, Pacemaker, External5 reports
- PRO PADZ 8900-4006Zoll Medical Corporation · PULSE-GENERATOR, PACEMAKER, EXTERNAL3 reports
- 5391Oscor Inc. · PULSE-GENERATOR, PACEMAKER, EXTERNAL1 death2 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 13, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page